Needle-Free Injections Market is Growing at a CAGR of 14.15% during the Forecast Period from 2021 to 2026 and will reach USD 24.12 billion by 2026, Affirms DelveInsight

LAS VEGAS, Dec. 6, 2021 /PRNewswire/ -- DelveInsight launched a new report on "Needle-Free Injections Market & Competitive Landscape," providing in-depth market understanding for Needle-Free Injections, which will further benefit the competitors or stakeholders operating in the Needle-Free Injections arena. 

Recent Developmental Activities in Needle-Free Injections Market

• In August 2021, PharmaJet and their partner Zydus Cadila announced the emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D, the world's first Plasmid DNA Vaccine for COVID-19. The vaccine- ZyCoV-D is exclusively administered by deploying the PharmaJet Tropis® Needle-free Injection System.
• In October 2020, PharmaJet's Needleless vaccine injector was chosen to deliver one of the COVID-19 vaccines- the University of Cambridge's phase 1 trial of DIOSynVax's candidate. The trial will test the delivery of the vaccine through the skin without using needles.

Interested in knowing how the Needle-Free Injections Market will be growing by 2026? Click to get a snapshot of Needle-Free Injections Market Analysis.

Needle-Free Injections Overview 

Needle-free injection technology (NFIT) is a tremendously broad notion that comprises a wide range of drug delivery systems that delivers drugs through the skin by any of the forces such as Lorentz, Shock waves, pressure by gas or electrophoresis, which forces the drug through the skin, almost abolishing the use of a hypodermic needle. 

This is beneficial for the pharmaceutical industry, and developing countries find it extremely valuable in mass immunisation programs, avoiding the chances of needle stick injuries and other complications, including those arising due to multiple uses of a single needle. These devices can be categorised based on their working, type of load, mechanism of drug delivery and site of delivery.

According to the World Health Organization (WHO) 2021, in 2019, the number of individuals affected with diabetes has increased drastically from 108 million in 1980 to 422 million in 2014. According to the data provided by the International Diabetes Federation (IDF) Diabetes Atlas Ninth Edition 2019, there were approximately 463 million adults in the age group 20-79 years and is expected to reach 700 million by 2045. 

Geography-Wise Needle-Free Injections Market Analysis 

Geographically, the global Needle-Free Injections market is studied for North America, Europe, Asia-Pacific, and the Rest of the World. In terms of revenue share, North America is expected to account for the largest share in the needle-free injections market because of the high prevalence of chronic diseases, increase in the awareness regarding needle-free injections, improving disposable income, and better healthcare infrastructure along with the presence of major market players in the region among other factors in the region. 

One of the key factors supporting the growth of the Needle-Free Injections market in the region is the high prevalence of diabetes. According to the Centers for Disease Control and Prevention 2021, almost 34 million people in the United States have diabetes, with 90-95% of them having type 2 diabetes. Therefore, an increase in the prevalence rate of the diabetes suffering population will lead to a greater demand for Needle-Free Injections in the market, further elevating the market growth. 

Furthermore, the growing collaborations between the needle-free injection devices manufacturers and pharmaceutical companies in the region are further driving the needle-free injections market in the United States, and therefore in North America.

To know more why North America is leading the market growth in the Needle-Free Injections market, get a snapshot of Needle-Free Injections market report 

There are great opportunities for Needle-Free Injections market penetration for countries like China, India, and Japan as the prevalence rate is high. According to the IDF Diabetes Atlas 9th Edition, an estimated 87.6 million adults aged 20-79 years were living with diabetes in the South-East Asia region in 2019, representing a regional prevalence of 8.8%. This is expected to increase to 153 million by 2045. It is estimated that around 60% of diabetics in the world live in Asia.

Covid-19 Impact on Needle-Free Injections Market 

The demand for Needle-Free Injections is primarily affected by the outbreak of the COVID-19 pandemic because of the delay in the supply and manufacturing of the products. However, Type 2 diabetes, hypertension, and cardiovascular diseases have been identified as the most common comorbidities for SARS-CoV-2 infection and have been associated with worse outcomes and more severe courses of COVID-19. It was estimated that 10% of COVID-19 vaccine hesitancy maybe because of needle phobia, creating a demand for alternative delivery routes to clear a barrier to vaccination, such as Needle-Free Injections.

The demand for Needle-Free Injections was boosted by the approval of vaccines like Zydus' vaccine, which will be administered by needle-free injections in August 2021. In September 2021, Scancell advanced its effort to provide an alternative by tapping PharmaJet for needle-free delivery technologies. It is approved in South Africa to run a phase I clinical trial of the vaccine candidates in July, where the investigators will administer the vaccines using the PharmaJet Tropis and PharmaJet Stratis needle-free injection systems.

To discuss more the short/long-term impact of COVID-19 get a snapshot of the Needle-Free Injections market insight report 

Needle-Free Injections Market Segmentation

• By Product Type
• Insulin Syringes
• Fillable
• Prefilled
• By Technology
• Jet-Based
• Spring-Based
• Others 
• By Usability
• Reusable
• Disposable
• By Application
• Vaccine
• Insulin
• Dermatology
• Others
• End-User
• Hospitals
• Clinics
• Homecare Settings
• Others
• By Geography
• North America
• Europe
• Asia-Pacific
• Rest of World

Needle-Free Injections Market Segment Analysis 

According to the estimates, in the product type segment of the Needle-Free Injections market, the application segment of the needle-free injections market, the insulin delivery needle-free injections are expected to account for the significant share in the market during the forecast period. Diabetics require multiple doses of insulin in a day, which can be a daunting process for patients in case of using conventional syringes and needles for insulin administration. These devices aid in the easy administration of insulin through the nozzle orifice, which results in the generation of a fine stream of insulin. Needle-free insulin injection systems offer the least resistant path for insulin administration, thereby facilitating the even spreading of insulin in the subcutaneous layer. Hence, the launch of new innovative products, various other factors such as user-friendly design, rising popularity, and adoption rate among the patient population are also anticipated to contribute to the Needle-Free Injections market growth.

Needle-Free Injections Market Scope

• Study Period: 2018-2026
• Key Companies: IntegriMedical LLC, INJEX Pharma GmbH, PharmaJet Corporation, CrossJect, European Pharma Group BV, National Medical Products Inc, Akra DermaJet, Meika Medical Co, Basco India., Mystic Pharmaceuticals Inc, Technologies Médicales Internationales (MIT Canada) Inc., INOVIO Pharmaceuticals, MADA MEDICAL PRODUCTS INC.,  Portal Instruments, D'Antonio Consultants International, Inc and others.
• Analysis: The Needle-Free Injections market is expected to grow at a CAGR of 14.15% during the forecast period from 2021 to 2026 to reach 24.12 billion by 2026.

Table of Contents 

Related Reports

• Diabetes Market 

DelveInsight's Diabetes Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the market and Competitive Landscape analysis.  Key players involved in this market are BD, Medtronic, Terumo Group, F Hoffmann-La Roche Ltd., BIGFOOT BIOMEDICAL, INC, Eli Lilly and Company, Novo Nordisk A/S and others.

• Diabetes Pen Market & Competitive Landscape 

DelveInsight's Diabetes Pen Market-Market Insights, Competitive Landscape and Market Forecast–2026 report delivers an in-depth understanding of the market and Competitive Landscape analysis. Key players involved in this market are BD, Medtronic, Terumo Group, F Hoffmann-La Roche Ltd., BIGFOOT BIOMEDICAL, INC, Eli Lilly and Company, Novo Nordisk A/S, and others.

• Injectable Drug Delivery Devices Market & Competitive Landscape

DelveInsight's Injectable Drug Delivery Devices Market Insights, Competitive Landscape and Market Forecast–2026 report delivers an in-depth understanding of the market and Competitive Landscape analysis.  Key players involved in this market Eli Lilly and Company, Biocon, Becton, Dickinson & Company, West Pharmaceutical Services, Inc., Johnson & Johnson, Antares Pharma, AbbVie Inc., Pfizer Inc., Mylan N.V., Vetter Pharma-Fertigung GmbH & Co.KG, Emperra GmbH, Gerresheimer AG, SCHOTT AG, Terumo Corporation and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Business Consulting Services with a credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach. 

Contact Us:
Shruti Thakur
[email protected]   
+1(919)321-6187
www.delveinsight.com

SOURCE DelveInsight Business Research, LLP